The compound has become one of the most recognised peptides within modern research literature due to its defined molecular structure, reproducible analytical profile and extensive use in experimental peptide investigations

Introduction Evidence from observational studies shows that use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with various health benefits,1 including reduced risks of incident alcohol use disorder23 and incident cannabis use disorder4 and reduced frequency of healthcare encounters for tobacco use disorder.5 However, much less is known about the association between GLP-1 receptor agonists and risks of developing other substance use disorders (SUDs), such as opioid use disorder and stimulant use disorder.6 Observational studies within populations with a pre-existing SUD have also emerged suggesting that use of GLP-1 receptor agonists is associated with reduced risks of adverse events such as opioid overdose,78 alcohol intoxication,7 and risk of hospital admission for alcohol use disorder.9 While the evidence base is growing, it does not comprehensively include all common SUDs

These medications mimic the effects of natural GLP-1 hormones in the body, slowing digestion and promoting a feeling of fullness, resulting in steady and sustainable weight loss
It suggests that GLP-1 receptor agonists may protect the kidney independently of glycemic control, through direct cellular maintenance pathways an insight that bridges metabolism and organ protection (CKM axis)
TB-500, a synthetic version related to thymosin beta-4 research, is commonly explored for cell migration, tissue remodeling, and recovery-related biological processes